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52 and 20%, respectively. Death (n = 59, 98%) was attributed 
mainly to disease progression with cachexia and metastases, 
pneumonia (n = 5, 10%), and hemoptysis (n = 1, 2%).  Conclu-
sion: UltraflexTM stents have a low complication rate and can 
be effectively used in complex malignant airway stenoses 
 with marked asymmetry or irregularity, angulation or chang-
ing diameters.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Interventional bronchoscopy methods are useful tools 
to relieve central airway stenosis due to inoperable ma-
lignant tumor, which may lead to respiratory distress and 
infection. If the obstruction is exclusively or mainly due 
to compression from outside the airway wall, the only op-
tion consists of placement of a stent or endoprosthesis  [1, 
2] . A variety of different stent models including the Du-
mon silicone stent  [3–6] , hybrid stents  [7] and self-ex-
panding metallic stents  [8–10] have been commercially 
available over the last 20 years. The Dumon stent has 
been commonly used worldwide. It is also economical 
and can easily be removed, even if it has been in place for 
an extended time  [3–6] . The main advantages of self-ex-
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 Abstract 
 Background: Despite being commercially available for a few 
years now, the literature regarding the outcome of Ultra-
flexTM stent insertion in complex malignant airway stenoses 
is sparse.  Objectives: To assess long-term complications and 
survival in patients with complex malignant airway stenoses 
treated with insertion of nitinol stents.  Methods: 60 consec-
utive patients with UltraflexTM stent insertion for malignant 
airway stenoses were included. Follow-up was obtained in 
all patients.  Results: 62 UltraflexTM stents (covered = 51, un-
covered = 11) were implanted in 60 patients. Diagnoses were 
bronchial carcinoma (n = 50), esophageal carcinoma (n = 3) 
and metastases (n = 7). Stents were inserted in the trachea 
(n = 5), main bronchi/intermediate bronchus (n = 22), from 
main bronchi/intermediate bronchus to lobar bronchi (n = 
28) or in the lobar bronchi themselves (n = 7). Successful re-
opening of the stenoses and relief were achieved in all pa-
tients. There was no procedure-related mortality. Complica-
tions included mucous plugging in 8%, stenosing granula-
tion tissue in 5%, tumor ingrowth in 5% and stent migration 
in 5% of patients. Using Kaplan-Meier estimates, the overall 
mean survival was 160 days (standard error: 30). Median sur-
vival was 91 days. The overall 3- and 6-month survival were 
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pandable metallic stents over tubular silicone stents are 
better adaptability to varying airway diameters, absence 
of kinking and favorable internal to external diameter 
ratio  [8–10] . A recent development has been that of the 
UltraflexTM nitinol stent, a self-expanding, knitted me-
tallic mesh made from nitinol, a nickel-titanium alloy 
 [11–14] . Nitinol has much greater elasticity than stainless 
steel and shows a nonlinear behavior with hysteresis in 
stress-strain tests similar to cartilage  [15, 16] . These phys-
iological properties may prevent damage to the mucosa, 
because the alloy exhibits low resistance to cough. At the 
same time, it exhibits adequate resistance to airway com-
pression by the tumor. The knitted design of the Ultra-
flexTM stent permits axial and radial movements of the 
wire filaments which allows excellent adaptation and 
prevents longitudinal expansion of the stent when com-
pressed radially. Despite being commercially available for 
a few years now, the literature regarding the outcome of 
this device in complex malignant airway stenoses is 
sparse.
 We have been using the UltraflexTM stent for malig-
nant airway stenoses with marked asymmetry or irregu-
larity, lesions with angulation and those with changing 
diameters. These lesions are not well suited for treatment 
with relatively rigid tubular silicone stents. We under-
took this study to assess the long-term complications and 
survival in patients with such complex malignant airway 
stenoses after insertion of nitinol stents.
 Methods 
 Sixty consecutive patients undergoing UltraflexTM stent inser-
tion for malignant airway stenosis between September 1997 and 
September 2003 were analyzed retrospectively. Prior to stent in-
sertion, all patients underwent evaluation by flexible bronchos-
copy to establish the nature of the central airway obstruction and 
plan the therapeutic procedure. This was necessary because at 
that time we introduced most metallic stents by rigid bronchos-
copy under general anesthesia that had to be planned in advance. 
Indications for stent insertion were central airway obstruction in 
the trachea and main bronchi down to lobar levels due to tumor 
or unstable airway walls, symptoms due to central airway ob-
struction (dyspnea, infection, cough, hemoptysis), diameter of af-
fected airway  ! 50% of normal after bronchoscopic resection of 
endoluminal components of obstruction, and estimated survival 
 1 30 days. UltraflexTM stents were chosen by the treating physician 
because the anatomical situation was considered as not suitable 
for a tubular silicone stent. Such situations included markedly ir-
regular stenoses (i.e. of the trachea), curved or angular stenoses 
(i.e. lesions extending from the trachea to a main bronchus after 
long-standing occlusion of the other side), conical stenoses, and 
lesions extending to the proximal lobar bronchi or of the lobar 
bronchi themselves.
 The commercially available UltraflexTM stent (Boston Scien-
tific, Galway, Ireland) was used. This stent is fixed onto an intro-
ducing catheter and maintained in its compressed form by a tight-
ly fitting string, which extends up to the proximal delivery han-
dle. By pulling the string the stent is deployed  [12–14] . The covered 
version has a polyurethane covering on the outside to prevent en-
dobronchial tumor encroaching in the airway lumen. Whenever 
possible covered stents were used. As short stents of 20 mm in 
length are not available in a covered version, uncovered stents 
were inserted in 7 patients for lobar stenoses, in 3 patients for ste-
noses extending from the right intermediate or the left main to a 
lower lobe bronchus and in 1 patient for stenosis of the bronchus 
intermedius.
 Laser ablation by Nd:YAG laser and/or dilatation with the rig-
id bronchoscope or a balloon catheter was performed as needed 
before stent placement  [2, 17] . Stent insertion was performed ei-
ther under fluoroscopic guidance and general anesthesia with the 
rigid bronchoscope or under direct vision and moderate sedation 
with the flexible bronchoscope (2 stents). For stent placement un-
der fluoroscopy (60 stents), radiopaque skin markers were placed 
on the chest to mark the distal and proximal ends of the stenosis 
with the help of a flexible bronchoscope. A guide wire was in-
serted through the working channel of the flexible bronchoscope 
into the stenotic airway. The flexible bronchoscope was then re-
moved and under fluoroscopic guidance the stent delivery system 
was advanced over the guide wire until the radiopaque skin mark-
ers of the stent delivery system were aligned with the skin mark-
ers. After positioning, the stent was deployed from its delivery 
catheter under fluoroscopic control  [14] . Two stents were inserted 
under direct vision by the bronchoscope. At the present time we 
prefer this technique and use it routinely either with rigid or flex-
ible bronchoscopy as it is easily performed without radiologic fa-
cilities and radiation exposure  [13] . All patients received nebu-
lized saline after stent insertion to prevent stent obstruction by 
secretions.
 Detailed clinical follow-up was available in all patients. Fol-
low-up data consisted of subsequent clinical visits, hospital docu-
ments, if patients had to be hospitalized, and information given 
by general practitioners who were contacted by letter and filled 
out a questionnaire. If questionnaires were not returned or the 
information given was not conclusive, the practitioners were con-
tacted by telephone. Lung function before and after intervention 
was available in 17 patients. Complications were recorded and 
judged to be stent-related or not. Bronchoscopy for removing de-
bris and suctioning secretions was performed 1 day after stent 
placement. Follow-up bronchoscopy at a later stage was not rou-
tinely carried out, but practitioners referred 23 patients (38%) suf-
fering from new symptoms to check for potential stent-related 
complications.
 The study was approved by the ethics committee of both can-
tons of Basel (Basel-City and Basel-Country).
 Statistical Analysis 
 Probabilities of survival were calculated using the Kaplan-
Meier estimates. The t test was used to compare the mean percent 
predicted FEV1 (forced expiratory volume in 1 s) before and after 
the procedure. Statistical analysis was performed using the statis-


























   
   
   
   

























 A total of 62 stents were inserted in 60 patients (43 
men) with a mean age of 62 years (range 39–79). All pa-
tients had either advanced inoperable lung cancer or pul-
monary metastases. Diagnoses were bronchial carcino-
ma (n = 50), esophageal carcinoma (n = 3), metastases of 
rectosigmoidal (n = 2), breast (n = 1), renal (n = 1) and 
cervical (n = 1) carcinoma and malignant lymphoma 
(n = 2). Forty-eight patients had not undergone any treat-
ment prior to stent placement, whereas 12 had received 
various cycles of chemotherapy and/or radiotherapy pri-
or to stent insertion. After stent insertion, chemotherapy 
was given to 26 patients because of metastatic disease and 
radiotherapy to 16 patients for local control.
 The stents used were combinations of various diame-
ters and lengths, the diameters varying from 10 to 18 mm, 
and the lengths from 20 to 60 mm. The sites of stent in-
sertion are presented in  figure 1 . The nature of the steno-
sis was extrinsic compression in 6 and mixed stenosis in 
56 cases. In 1 patient, there was incomplete deployment 
of the stent and the delivery device was removed and re-
placed with a new stent. In all other patients, the place-
ment was successful at the first attempt. Following stent 
insertion, successful reopening of the airways was noted 
in all patients. There was no procedure-related mortality. 
In the 17 patients who had undergone pulmonary func-
tion testing before and after stent placement, the mean 
( 8 standard deviation) FEV1 improved from 1.45  8 0.48 
to 1.78  8 0.62 liters (p = 0.003).
 Overall stent-related complications were seen in 23% 
of patients ( table 1 ). Stent obstruction due to tenacious 
secretions was noted in 5 patients (8%, after 14, 22, 30, 50, 
and 55 days, respectively), which was successfully re-
lieved by bronchoscopic suction in 4 patients. In 1 pa-
tient, the stent had to be removed due to dried, obstruct-
ing secretions. Stenosing granulation tissue formation at 
the stent ends was removed by forceps and laser in 3 pa-
tients (5%, after 53, 98, and 155 days, respectively). In 1 of 
these 3 patients, the stent was extracted in order to re-
move the granulation tissue more efficiently and subse-
quently a new stent was inserted. In the 2 patients in 
whom the stent remained in place the risk for ignition of 
the polyurethane cover was low, because the granulation 
tissue had developed at the uncovered stent ends. In ad-
dition, debris and blood were carefully removed from the 
polyurethane cover to minimize absorption of the laser 
light. A good alternative to laser would have been cryo-
therapy, which was not available at our institutions. Tu-
mor ingrowth occurred in 3 patients (5%, after 15, 20, and 
522 days, respectively). Treatment consisted of laser ther-
apy, brachytherapy or external radiation in 1 patient each. 
Stent migration was noted in 3 patients (5%, after 5, 15, 








IMBRLL Trachea LMB LUL or LLLRMB
 Fig. 1. Sites of stent implantation in 60 pa-
tients (62 sites). RMB = Right main bron-
chus; LMB = left main bronchus; IMB = 
intermediate bronchus; RLL = right lower 
lobe bronchus; LUL = left upper lobe bron-
chus; LLL = left lower lobe bronchus. The 
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ing of the existing stent, replacement with a larger stent, 
or stent removal in 1 patient each. Stent-related complica-
tions occurred after 13 of 51 (25%) implantations of cov-
ered stents and after 1 of 11 (9%) insertions of uncovered 
stents. Complications occurred after 2 of 6 (33%) implan-
tations of a stent with a length of 60 or 80 mm, with 11 of 
45 (24%) stents of 40 mm and with 1 of 11 (9%) stents of 
20 mm.
 Fifty-nine of 60 patients (98%) had died by September 
16, 2007. One patient with postobstructive pneumonia, 
who had improved after stent insertion, was offered pneu-
monectomy and survived longer than 4 years. Survival of 
the patients who had died ranged from 1 to 95 weeks. Two 
patients with advanced cancer and significant comorbid-
ities such as severe chronic obstructive pulmonary dis-
ease and advanced arteriosclerosis survived only 1 week. 
Death was not considered to be related to the intervention 
and in retrospect these patients had not been good can-
didates for stent placement. Using Kaplan-Meier esti-
mates, the overall mean survival was 160 days (standard 
error: 30). Overall median survival was 91 days. The 
overall 3- and 6-month survival were 52 and 20%, respec-
tively. The 3- and 6-month survival in patients who had 
stent insertion in the trachea or the main bronchi (called 
proximal stent placement by us) were 48 and 11%, respec-
tively, and in those in whom the stent extended to the 
lobar bronchi or had been placed only in the lobar bron-
chi (distal stent placement) the 3- and 6-month survival 
were 61 and 27%, respectively ( fig. 2 ). Death (n = 59) was 
mainly attributed to disease progression associated with 
cachexia and metastases. In 6 patients (12%), death was 
potentially related to local complications such as pneu-
monia (5 patients, 10%) and hemoptysis (1 patient, 2%).
 Discussion 
 In this study, we were able to demonstrate in a rela-
tively large number of patients that the UltraflexTM stent 
was effective in relieving complex malignant airway ob-
Complication Number
(%)
Intervention Days after insertion
  (length of stent)
Mucous plugging 5 (8%) 4 bronchoscopic suction
1 stent removed
50 (60 mm, covered) 
14, 22, 30, 55
(all 40 mm and covered)
Granulation tissue 3 (5%) 3 laser
1 stent replaced
98 (60 mm, covered)
155 (40 mm, covered)
53 (40 mm, covered)
Tumor restenosis 3 (5%) 1 laser
1 brachytherapy
1 external radiation
20 (60 mm, covered)
15 (40 mm, covered)
522 (40 mm, covered)
Stent migration 3 (5%) 1 stent repositioned
1 stent replaced
1 stent removed
5 (40 mm, covered)
85 (40 mm, covered)
15 (20 mm, uncovered)
Table 1. Stent-related complications
and interventions; in addition number
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p = 0.031
 Fig. 2. Kaplan-Meier survival in patients who had stent insertion 
in the trachea or the main bronchi (proximal) compared to those 
in whom the stent insertion extended to the lobar bronchi or had 
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struction with an acceptably low complication rate. Stent-
related complications during follow-up occurred in 23% 
of patients and included mucous plugging, stent migra-
tion as well as granulation tissue or tumor growth at the 
stent ends or through the stent wires. The overall 3- and 
6-month survival were 52 and 20%, respectively.
 There have been previous papers reporting complica-
tions during follow-up of patients after UltraflexTM stent 
implantation  [12, 18, 19, 20] . All the same, our study of-
fers some additional information, because we inserted 
UltraflexTM stents for complex stenoses mainly in the 
bronchi and not the trachea, the study group was rela-
tively large and we were able to obtain a close follow-up 
of each patient. Because we serve a relatively small area, 
we benefited from the close collaboration with general 
practi tioners who contacted us or sent patients back for 
consultation and bronchoscopy in case of worsening 
symptoms. The study by Miyazawa et al.  [12]  was the one 
most similar to ours, the stents were inserted mainly 
bronchially and patients were closely followed by routine 
examinations including bronchoscopy after 1 and 2 
months. However, the number of patients was smaller 
and uncovered stents were used. Madden et al.  [18, 19] 
 inserted mainly tracheal stents and treated more benign 
than malignant lesions so that comparison with our study 
is difficult. Recently, Husain et al.  [20]  reported on 66 
patients (12 with benign, 54 with malignant pathology) 
with mainly tracheal obstructions, who were treated by 
uncovered stents. Long-term data were collected by ques-
tionnaires sent to the general practitioners, but only 46 of 
54 questionnaires of patients with malignancies were 
completed. Median survival of those patients was 4 
months. Side effects (cough, hemoptysis, repeated infec-
tions, increased secretions, chest pain) possibly attribut-
able to the stent occurred in 3 of the 12 (25%) patients 
with benign disease and in 8 of the 48 patients (17%) with 
malignancies, according to the questionnaires. However, 
the true number of stent-related complications cannot be 
established without routine follow-up bronchoscopies or 
at least bronchoscopies in the case of unexplained dete-
riorations. Although routine follow-up bronchoscopies 
are not recommended by official guidelines  [1, 2] , they are 
important in studies.
 Mucous plugging with tenacious secretions is a com-
mon complication associated with stent placement and 
was found in 8% of our patients. This is comparable to the 
findings of Miyazawa et al.  [12] , who reported this com-
plication in 9% of patients after insertion of uncovered 
UltraflexTM stents for malignant airway lesions. Although 
we had expected the covered stents to have a higher rate 
of mucous plugging, this was not the case in our patients. 
This may be due to the fact that only the middle part of 
the stent is covered with a polyurethane layer, thus allow-
ing the stent extremities to become epithelialized. A 
higher rate of mucous plugging has been observed in 19–
38% of patients following Wallstent implantation, anoth-
er self-expanding metallic stent made of a cobalt alloy 
with a polyurethane cover  [8, 9] . This difference may be 
explained in part by the better adaptation of the Ultra-
flexTM stent to the airway wall and in part by the reduced 
stimulation of stenosing granulation tissue formation at 
its extremities, which would promote the retention of se-
cretions. In comparison, mucous obstruction has been 
reported with the Dumon silicone stent in 1.0–5.3%  [4, 6] 
of cases with malignant disease and in 6.3% of cases with 
benign tracheal stenosis  [5] , rates which seem to be simi-
lar to the ones with the UltraflexTM stent but lower than 
the ones with the Wallstent.
 Granulation tissue at the stent ends was observed in 
only 5% of cases in our study. This is considerably lower 
compared to the Wallstents, where stenosing granulation 
tissue has been seen in 10–15% of patients  [8, 9] . The 
Wallstent has sharp fibers at the stent ends and it also 
elongates with airway compression during cough thereby 
irritating the mucosa and thus stimulating granulation 
tissue formation. The fully open UltraflexTM stent has 
smooth ends, does not elongate on compression by cough-
ing and reduces irritation due to stent movement. The 
low granulation rate may also be explained in part by the 
short length of survival of the patients with malignant 
disease.
 No perforation of the airway wall was seen during the 
insertion of the stent or at follow-up. The UltraflexTM 
stent insertion is probably less traumatic in a subset of 
patients with curved or narrow airways than the Dumon 
stent, because the delivery device of the UltraflexTM stent 
can be passed through the obstruction without the need 
to intubate beyond the stenotic area with the rigid bron-
choscope. Nevertheless previous tumor debulking with 
laser, the bevel of the rigid bronchoscope or balloon dila-
tation before stent placement is still recommended for the 
assessment of the extent of the lesion and to assure the 
expansion of the stent  [14] .
 Tumor ingrowth within the stent lumen was observed 
in 5% of cases. This is in marked contrast to the report of 
Miyazawa et al. [12] , who reported tumor ingrowth in 
24% of patients. These results suggest that the covered 
nature of the UltraflexTM stent used in our study reduces 
tumor ingrowth compared to the uncovered stent type 
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of a covered UltraflexTM stent instead of an uncovered Ul-
traflexTM stent in the treatment of malignant endobron-
chial airway stenoses.
 The stent migration rate was 5%, which seems to be 
lower than after the implantation of silicone stents. Du-
mon et al. [4] reported a stent migration rate of 6% in 
malignant disease  and Bolliger et al.  [6]  a rate of 13.2%, 
especially in short and conical lesions. In benign tracheal 
and bronchial stenoses, the corresponding numbers are 
17.5–18.6%, probably due to longer survival  [4, 5] . The 
lower migration rate after UltraflexTM stent implantation 
may be explained by its better adaptation to the airway 
wall in irregularly shaped airways. Furthermore, the 
stent has uncovered parts at both the proximal and distal 
ends, which usually become epithelialized within a few 
weeks of stent insertion. The drawback, though, is the 
difficult removal of the UltraflexTM stent once it has been 
epithelialized  [21, 22] . Thus, a silicone stent is preferable 
in the setting of neoadjuvant treatment of malignant dis-
ease with the possibility of later removal. Furthermore, 
there are occasionally long-term survivors after addition-
al treatment with chemo- and/or radiotherapy, in whom 
removal of the stent might be desirable, i.e. after recur-
rent mucous plugging or development of stenosing gran-
ulation tissue.
 Due to their good adaptation to changing diameters 
and thin walls, UltraflexTM stents can be used in airway 
stenoses not well suited for rigid silicone stents, such as 
severely asymmetrical lesions, angular stenoses (i.e. le-
sions extending from the trachea to a main bronchus af-
ter pneumonectomy or after long-standing occlusion of 
the other side), conical stenoses, and lesions extending to 
the proximal lobar bronchi or of the lobar bronchi them-
selves. Stenoses extending from the intermediate or the 
left main to a lobar bronchus were observed in 27 (45%) 
of our patients (28 stents). A typical example is a tumor 
of the left upper lobe which also compresses the opening 
of the lower lobe bronchus. In this case, it might be desir-
able to place a stent from the main bronchus to the lower 
lobe bronchus ( fig. 3 ), which is only possible with a thin-
walled and well-adapting stent.
 Moreover, there were also 7 patients (12%) with steno-
ses due to compression confined to a lower lobe bronchus, 
a debatable indication for stenting. However, stenting of 
lobar bronchi may occasionally be helpful, i.e. in the case 
of recurrent postobstructive pneumonia, seriously inter-
fering with the administration of additional treatment 
such as chemotherapy or radiotherapy. Because short 
stents are not covered, we only recommend stent place-
ment in cases with compression and not in those with 
endoluminal growth, provided that most of the lobe is 
functional, i.e. in tumors either extending from another 
lobe or of the apical lower lobe segment leaving the basal 
segments unaffected.
 One could reason that stenting of distal compared to 
proximal lesions might cause a higher complication rate 
because of the small stent diameters. However, our data 
do not support this conclusion. On the contrary, survival 
after distal stent placement was even longer, possibly due 
to a smaller tumor load.
 In conclusion, UltraflexTM stents were effective in the 
management of complex malignant airway stenoses with 
a low complication rate. They may play a role in situations 
not suited for rigid tubular silicone stents, such as steno-
ses with marked asymmetry or irregularity, angulation 
or changing diameters. 
 Fig. 3. A typical example of a tumor of the 
left upper lobe which also compresses the 
opening of the lower lobe bronchus.  a Be-
fore stent implantation.  b After insertion 
of an UltraflexTM stent which extends from 
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